Interleukin-2 clinical trials.

Abstract

Patient selection criteria are presented for three clinical trials using low-dose Interleukin-2 (IL-2) to reconstitute the immune system in HIV-infected patients. These trials are being conducted by the New York Presbyterian Hospital-Cornell Medical Center. In addition to IL-2 therapy, patients will either continue on their existing anti-HIV treatment or receive other specific drug regimens, depending on the study. IL-2 appears to have few side effects and does not seem to stimulate viral replication. IL-2 may also provide certain benefits to the immune system.